184 related articles for article (PubMed ID: 22047509)
1. Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
Surati M; Patel P; Peterson A; Salgia R
Expert Opin Biol Ther; 2011 Dec; 11(12):1655-62. PubMed ID: 22047509
[TBL] [Abstract][Full Text] [Related]
2. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
3. [A new drug in thoracic oncology: MetMab (onartuzumab)].
Giroux Leprieur É
Rev Pneumol Clin; 2013 Jun; 69(3):152-8. PubMed ID: 23477747
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
Sadiq AA; Geynisman DM; Salgia R
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1810-1. PubMed ID: 22005540
[No Abstract] [Full Text] [Related]
5. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
6. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciardiello F; Gridelli C
Curr Pharm Des; 2012; 18(37):6155-68. PubMed ID: 22873759
[TBL] [Abstract][Full Text] [Related]
7. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
[TBL] [Abstract][Full Text] [Related]
8. [Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer].
Jiang T; Zhou C
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):240-4. PubMed ID: 25936889
[TBL] [Abstract][Full Text] [Related]
9. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
10. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.
Catenacci DV; Henderson L; Xiao SY; Patel P; Yauch RL; Hegde P; Zha J; Pandita A; Peterson A; Salgia R
Cancer Discov; 2011 Dec; 1(7):573-9. PubMed ID: 22389872
[TBL] [Abstract][Full Text] [Related]
11. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Faus-Dáder MJ; Calleja-Hernández MÁ
Pharmacol Res; 2015 Dec; 102():90-106. PubMed ID: 26413995
[No Abstract] [Full Text] [Related]
12. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
[TBL] [Abstract][Full Text] [Related]
13. Targeting the HGF/Met signaling pathway in cancer therapy.
Cecchi F; Rabe DC; Bottaro DP
Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
[TBL] [Abstract][Full Text] [Related]
14. MET as a possible target for non-small-cell lung cancer.
Sadiq AA; Salgia R
J Clin Oncol; 2013 Mar; 31(8):1089-96. PubMed ID: 23401458
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
17. C-MET inhibitors in the treatment of lung cancer.
Goździk-Spychalska J; Szyszka-Barth K; Spychalski L; Ramlau K; Wójtowicz J; Batura-Gabryel H; Ramlau R
Curr Treat Options Oncol; 2014 Dec; 15(4):670-82. PubMed ID: 25266653
[TBL] [Abstract][Full Text] [Related]
18. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
[TBL] [Abstract][Full Text] [Related]
19. C-MET inhibitors for advanced non-small cell lung cancer.
Pasquini G; Giaccone G
Expert Opin Investig Drugs; 2018 Apr; 27(4):363-375. PubMed ID: 29621416
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]